Treatmentresistant

NEW YORK and BERLIN, Jan. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company focused on mental health, announced that, while PCN-101 (R-ketamine)…

Lori Solomon THURSDAY, Dec. 29, 2022 (HealthDay News) -- The U.S. Food and Drug Administration has approved Sunlenca (lenacapavir), a new type of antiretroviral medication for adult patients living with…

Lori Solomon THURSDAY, Dec. 22, 2022 (HealthDay News) -- Treatment-resistant depression (TRD) is associated with a heavy individual and societal burden, according to a study published online Dec. 14 in…

Aldosterone and renin biomarker activity clinically demonstrate how baxdrostat mechanistically achieves selective blood pressure lowering effects with no impact on cortisol 20.3 mmHg reduction in systolic blood pressure, or 11 mmHg…

Clinically significant and dose-dependent reduction in blood pressure with baxdrostat Highly selective mechanism of action with no meaningful impact on cortisol supports first-in-class potential Potential treatment for the 10-12 million…

Researchers at Trinity College Dublin have participated in the largest and most rigorous clinical trial to date of psilocybin (a psychoactive ingredient in magic mushrooms), pointing to the possibility that COMP360 psilocybin with…

Pune, India, Nov. 04, 2022 (GLOBE NEWSWIRE) -- The global treatment-resistant depression treatment market size was valued at USD 1.52 billion in 2021. The market is projected to grow from USD 1.55 billion in 2022 to USD 2.83 billion by…

Investigators from Cedars-Sinai Cancer have identified an investigational therapeutic approach that could be effective against treatment-resistant prostate cancer. Results of their Phase II clinical trial, published in the peer-reviewed…

Research led by doctors and scientists at UCLA Jonsson Comprehensive Cancer Center and the UCLA Jane & Terry Semel Institute for Neuroscience & Human Behavior have identified a gene that may provide a therapeutic target for the…

Targeted therapies specifically attach to and hinder cancer-causing proteins, but cancer cells can quickly evolve to thwart their action. A second drug class, immunotherapies, harnesses the immune system to attack cancer cells, but these…